Overview

Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or normal renal function who were administrated subcutaneously single dose PEX168.To evaluate dose adjustment of PEX168 administered in patients with renal insufficiency and provide a scientific basis in patients with renal insufficiency of rational drug use.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.